SGLT2 Inhibitors Safe for KTRs, Data Show
The safety profile of SGLT2 inhibitors in kidney transplant recipients with type 2 diabetes is similar to that of other patient populations, new research suggests.
The safety profile of SGLT2 inhibitors in kidney transplant recipients with type 2 diabetes is similar to that of other patient populations, new research suggests.
Kidney transplant recipients who had nonfatal MACE within the first year after transplant surgery, compared with those who did not, had a significantly lower 1-year survival rate (80.5% vs 97.4%).
Authors say review findings are limited by heterogenous definitions of long COVID in published studies
Fewer renal complications seen with tirzepatide versus insulin glargine in adults with T2D and increased cardiovascular risk
The EMPRISE study assessed the efficacy and safety of empagliflozin use in approximately 500,000 adults with type 2 diabetes.
Adults with new onset type 2 diabetes in 2 years after diagnosis had increased risk of all-cause mortality
Patients with CKD are vulnerable to fractures due to CKD mineral bone disorder.
The increased death risk associated with type 2 diabetes in kidney transplant recipients does not vary significantly by body mass index, according to investigators.
No reduction seen in first occurrence of nonfatal MI, stroke, or CV death with either metformin or lifestyle intervention versus placebo
Greater glycemic variability is associated with increased risk for major adverse cardiovascular events